A Phase 2 ready biased APJR agonist ANPA-0073 for potential selective or muscle-sparing weight loss
Latest Information Update: 03 Oct 2025
At a glance
- Drugs ANPA-0073 (Primary)
- Indications Weight loss
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 03 Oct 2025 New trial record
- 06 Aug 2025 According to a Structure Therapeutics media release, company is evaluating ANPA-0073, a Phase 2 ready biased APJR agonist for potential selective or muscle-sparing weight loss.